initial public offerings (IPOs) trading on American exchanges

Thursday, December 5, 2013

Tandem Diabetes Care (TNDM) began trading on the NASDAQ on 14 November 2013


Tandem Diabetes Care, Inc. is a medical device company with an approach to the design, development and commercialization of products for people with insulin-dependent diabetes. The Company designed and commercialized its flagship product, the t:slim Insulin Delivery System, or t:slim, based on its technology platform and consumer-focused approach. Its technology platform features Micro-Delivery Technology, a miniaturized pumping mechanism, which draws insulin from a flexible bag within the pump’s cartridge rather than relying on a syringe and plunger mechanism. The Company also applies the science of human factors to its design and development process, which seeks to optimize its devices to the intended users, allowing users to successfully operate the devices in their intended environment.


Suite 200, 11045 Roselle Street
United States 

Key stats and ratios

Q3 (Sep '13)2012
Net profit margin-167.96%-1334.11%
Operating margin-155.96%-1335.44%
EBITD margin--1252.28%
Return on average assets-97.19%-122.74%
Return on average equity--

No comments:

Post a Comment